| National Stock Exchange of India Limited | BSE Limited |
| :--- | :--- |
| Exchange Plaza | Phiroze Jeejeebhoy Towers |
| Bandra Kurla Complex, Bandra (E) <br> Mumbai- 400051 | Dalal Street <br> Mumbai -400001 |
| Scrip Code: - TRIDENT | Scrip Code: -521064 |

## Sub: Update on Independent Rating by CRISIL on Quarterly Results of Company

## Dear Sirs,

In terms of the applicable provisions of the Listing Agreement entered into by the Company, we would like to inform you that CRISIL has issued Results update on Financial Results for the quarter and year ended March 31, 2015 of Trident Limited and has assigned the fundamental grade ' $3 / 5$ ' to the Company. The grade indicates that the Company's fundamentals are "good" relative to other listed equity securities in India. CRISIL Equity has assigned a valuation grade of ' $5 / 5$ ' indicating that market price has 'strong upside' from the current levels.

A copy of the Report released by CRISIL is enclosed for your kind information please.
This is for your kind information please.
Thanking you,
Yours sincerely,
For Trident Limited


## CR|S\|LIER Independent Equity Research



Enhancing investment decisions

Explanation of CRISIL Fundamental and Valuation (CFV) matrix
The CFV Matrix (CRISIL Fundamental and Valuation Matrix) addresses the two important analysis of an investment making process - Analysis of Fundamentals (addressed through Fundamental Grade) and Analysis of Returns (Valuation Grade) The fundamental grade is assigned on a five-point scale from grade 5 (indicating Excellent fundamentals) to grade 1 (Poor fundamentals) The valuation grade is assigned on a fivepoint scale from grade 5 (indicating strong upside from the current market price (CMP)) to grade 1 (strong downside from the CMP).

| CRISIL <br> Fundamental Grade | Assessment | CRISIL <br> Valuation <br> Grade | Assessment |
| :---: | :--- | :--- | :--- |
| $5 / 5$ | Excellent fundamentals | $5 / 5$ | Strong upside ( $>25 \%$ from CMP) |
| $4 / 5$ | Superior fundamentals | $4 / 5$ | Upside (10-25\% from CMP) |
| $3 / 5$ | Good fundamentals | $3 / 5$ | Align $(+-10 \%$ from CMP) |
| $2 / 5$ | Moderate fundamentals | $2 / 5$ | Downside (negative $10-25 \%$ from CMP) |
| $1 / 5$ | Poor fundamentals | $1 / 5$ | Strong downside (<-25\% from CMP) |

About CRISIL Limited
CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

About CRISIL Research
CRISIL Research is India's largest independent integrated research house. We provide insights, opinion and analysis on the Indian economy, industry, capital markets and companies. We also conduct training programs to financial sector professionals on a wide array of technical issues. We are India's most credible provider of economy and industry research. Our industry research covers 86 sectors and is known for its rich insights and perspectives. Our analysis is supported by inputs from our network of more than 5,000 primary sources, including industry experts, industry associations and trade channels. We play a key role in India's fixed income markets. We are the largest provider of valuation of fixed income securities to the mutual fund, insurance and banking industries in the country. We are also the sole provider of debt and hybrid indices to India's mutual fund and life insurance industries. We pioneered independent equity research in India, and are today the country's largest independent equity research house. Our defining trait is the ability to convert information and data into expert judgements and forecasts with complete objectivity. We leverage our deep understanding of the macro-economy and our extensive sector coverage to provide unique insights on micro-macro and cross-sectoral linkages. Our talent pool comprises economists, sector experts, company analysts and information management specialists.

CRISIL Privacy
CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of McGraw Hill Financial you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit www.crisil.com/privacy. You can view McGraw Hill Financial's Customer Privacy Policy at http://www.mhfi.com/privacy.

Last updated: August, 2014
Analyst Disclosure
Each member of the team involved in the preparation of the grading report, hereby affirms that there exists no conflict of interest that can bias the grading recommendation of the company.

Disclaimer:
This Company commissioned CRISIL IER report is based on data publicly available or from sources considered reliable. CRISIL Ltd. (CRISIL) does not represent that it is accurate or complete and hence, it should not be relied upon as such. The data / report is subject to change without any prior notice. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The subscriber / user assume the entire risk of any use made of this data / report. CRISIL especially states that, it has no financial liability whatsoever, to the subscribers / users of this report. This report is for the personal information only of the authorised recipient in India only. This report should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person - especially outside India or published or copied in whole or in part, for any purpose. As per CRISIL's records, none of the analysts involved has any ownership / directorship in the company. However CRISIL or its associates may have commercial transactions with the company.

## Trident Ltd

## Production ramp-up is a key monitorable

Fundamental Grade
Valuation Grade
Industry

Trident Ltd's Q4FY15 revenues were in line but EBITDA margin expanded more than CRISIL Research's expectations. Revenues were flat y-o-y at ₹9,780 mn as growth in terry towel sales ( $\sim 30 \%$ y-o-y) was offset by decline in sales of yarn (down 30\% y-o-y) and paper (down $3 \%$ y-o-y). EBITDA margin expanded by 443 bps $y-o-y$ and 283 bps q-o-q to $20 \%$ as the company benefited from lower cost of raw materials and higher sales contribution from the terry towel segment. PAT increased $39 \%$ y-o-y and $69 \%$ q-o-q to ₹ 407 mn but was lower than our expectations because of higher interest expense and tax provisions. We maintain our fundamental grade of $3 / 5$.

## Healthy growth traction in the terry towel segment

The terry towel segment's sales growth of $30 \%$ y-o-y was driven by $25 \%$ y-o-y growth in sales volume. Utilisation in the new terry towel production unit increased to $40 \%$ and is expected to further increase to $50-55 \%$ in FY16. Towel sales for FY15 increased $\sim 14 \%$ y-0-y driven by $17 \%$ y-o-y growth in sales volume. Yarn sales declined $30 \%$ y-o-y because of lower realisations and increase in captive consumption; FY15 yarn sales declined 18\% y-o-y. We expect yarn sales to remain largely flat over FY15-17 unlike our earlier expectations of improvement in growth.

## EBITDA margin expansion driven by lower material cost and profitable product mix

Cost of raw materials declined as the company offloaded high-cost cotton inventory last quarter and procured lower-cost cotton, resulting in margin improvement. It typically keeps five months of raw materials. In addition, sales contribution from terry towels increased from $32 \%$ in Q4FY14 to $\sim 47 \%$ in Q4FY15. As a result, EBITDA margin in textiles improved from $15 \%$ in Q4FY14 to $19.9 \%$ in Q4FY15. We expect EBITDA margin to expand from $18.3 \%$ in FY15 to $18.5 \%$ in FY16 and 19\% in FY17 driven by 20-25\% sales contribution from cotton bed sheets.

## Production ramp-up in bed sheet unit is expected to be slower than expected

The company has earmarked ₹16.5 bn as capex to set up bed sheet composite capacity, which is expected to get commissioned in 2HFY16. We expect ramp-up in production of the new bed sheet unit to be slower because of customer approvals and operational stabilisation. Accordingly, we have lowered our FY16 and FY17 average utilisation rate from 15\% and 55\% to $10 \%$ and $40 \%$ respectively.

## Lowered FY16-17 earnings estimates and fair value from ₹ 31 to ₹ 29 per share

We have lowered FY16 and FY17 revenue estimates from ₹47 bn and ₹57 bn to ₹44 bn and ₹53 bn, respectively. Resultantly, PAT estimates are revised from ₹ 1.6 bn and ₹ 2.2 bn to $₹ 1.4$ bn and ₹1.8 bn, respectively. Our DCF-based fair value estimate is reduced from ₹ 31 to $₹ 29$ per share. At the current market price of ₹23, our valuation grade is $\mathbf{5 / 5}$.

| KEY FORECAST |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
| (₹ mn) | FY13 | FY14 | FY15\# | FY16E | FY17E |
| Operating income | 33,947 | 38,775 | 37,860 | 44,359 | 53,416 |
| EBITDA | 5,673 | 7,405 | 6,915 | 8,221 | 10,167 |
| Adj net income | 455 | 1,956 | 1,178 | 1,442 | 1,774 |
| Adj EPS (₹) | 1.5 | 6.3 | 2.5 | 2.8 | 3.5 |
| EPS growth (\%) | $(212.1)$ | 329.4 | $(60.8)$ | 15.2 | 23.0 |
| Dividend yield (\%) | - | 1.8 | 2.1 | 2.5 | 3.0 |
| RoCE (\%) | 10.4 | 16.4 | 10.8 | 9.4 | 10.8 |
| RoE (\%) | 6.7 | 23.9 | 9.9 | 9.6 | 10.9 |
| PE (x) | 16.4 | 3.8 | 9.7 | 8.5 | 6.9 |
| P/BV (x) | 1.1 | 0.8 | 0.8 | 0.8 | 0.7 |
| EV/EBITDA (x) | 5.2 | 3.5 | 5.4 | 5.8 | 4.3 |

NM: Not meaningful; CMP: Current market price
Source: Company, CRISIL Research estimates

June 12, 2015
Fair Value ₹29
CMP ₹23
CFV MATRIX


## KEY STOCK STATISTICS

NIFTY/SENSEX
7983/26425
NSE/BSE ticker
TRIDENT/TRIDENT
Face value (₹ per share)
10
Shares outstanding (mn)
508.5

Market cap (₹ mn)/(US\$ mn)
11,652/184
Enterprise value (₹ mn)/(US\$ mn) 29,758/465
52-week range (₹)/(H/L)
34/16
Beta
0.9

Free float (\%)
33.4\%

Avg daily volumes (30-days) 229,397
Avg daily value (30-days) (₹ mn)
5.8

## SHAREHOLDING PATTERN



PERFORMANCE VIS-À-VIS MARKET

|  | Returns |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
|  | 1-m | 3-m | 6-m | 12-m |
| Trident | $0 \%$ | $-2 \%$ | $-14 \%$ | $-3 \%$ |
| CNX 500 | $-2 \%$ | $-9 \%$ | $-2 \%$ | $7 \%$ |

ANALYTICAL CONTACT
Bhaskar Bukrediwala bhaskar.bukrediwala@crisil.com
Abhijeet Singh
abhijeet.singh@crisil.com
Client servicing desk
+91 2233423561
clientservicing@crisil.com

## CRISIL IER Independent Equity Research

## Q4FY15 results summary (consolidated)

| ( $₹ \mathrm{mn}$ ) | Q4FY15 | Q3FY15 | Q4FY14 | q-o-q (\%) | y-0-y (\%) | FY15 | FY14 | y-0-y (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 9,780 | 9,313 | 9,902 | 5\% | -1\% | 37,843 | 38,840 | -3\% |
| Raw materials cost | 4,783 | 4,852 | 5,533 | -1\% | -14\% | 19,294 | 20,520 | -6\% |
| Raw materials cost (\% of net sales) | 48.9\% | 52.1\% | 55.9\% | -320bps | -698bps | 51.0\% | 52.8\% | -3\% |
| Other expenses | 969 | 893 | 816 | 8\% | 19\% | 3,870 | 2,870 | 35\% |
| Employee cost | 2,076 | 1,972 | 2,016 | 5\% | 3\% | 7,764 | 8,023 | -3\% |
| EBITDA | 1,953 | 1,595 | 1,537 | 22\% | 27\% | 6,915 | 7,428 | -7\% |
| EBITDA margin | 20.0\% | 17.1\% | 15.5\% | 283bps | 444bps | 18.3\% | 19.1\% | -85bps |
| Depreciation | 829 | 793 | 640 | 5\% | 30\% | 3,213 | 2,684 | 20\% |
| EBIT | 1,123 | 803 | 897 | 40\% | 25\% | 3,702 | 4,744 | -22\% |
| Interest and finance charges | 536 | 496 | 479 | 8\% | 12\% | 2,060 | 2,103 | -2\% |
| Operating PBT | 587 | 307 | 418 | 91\% | 41\% | 1,643 | 2,641 | -38\% |
| Other income | 1 | 3 | 3 | -78\% | -76\% | 37 | 11 | 245\% |
| PBT | 588 | 310 | 421 | 90\% | 40\% | 1,680 | 2,651 | -37\% |
| Tax | 181 | 69 | 128 | 163\% | 41\% | 500 | 681 | -27\% |
| PAT | 407 | 241 | 293 | 69\% | 39\% | 1,180 | 1,970 | -40\% |
| Adj PAT | 407 | 241 | 293 | 69\% | 39\% | 1,180 | 1,970 | -40\% |
| Adj PAT margin | 4.2\% | 2.6\% | 3.0\% | 157bps | 121bps | 3.1\% | 5.1\% | -195bps |
| No. of equity shares (mn) | 508.5 | 508.5 | 311.1 | - | - | 508.5 | 311.1 | - |
| Adj EPS (₹) | 0.8 | 0.5 | 0.9 | 69\% | -15\% | 2.5 | 6.3 | -63\% |

Source: Company, CRISIL Research

Revenues flat y-o-y but margin expanded more than expectations


[^0]Growth in terry towel sales was offset by decline in yarn sales


[^1]Sales contribution of terry towels improved $\mathrm{y}-\mathrm{O}-\mathrm{y}$


Source: Company, CRISIL Research

-Indexed to 100
Source: NSE, CRISIL Research

EBITDA margin of textiles improved significantly


Source: Company, CRISIL Research


Source: NSE, BSE, CRISIL Research

Earnings Estimates Revised Downwards

| Particulars | Unit | FY16E |  |  | FY17E |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Old | New | \% change | Old | New | \% change |
| Revenues | (₹ mn) | 46,691 | 44,359 | -5\% | 57,229 | 53,416 | -7\% |
| EBITDA | (₹ mn) | 8,651 | 8,221 | -5\% | 10,892 | 10,167 | -7\% |
| EBITDA margin | \% | 18.5\% | 18.5\% | Obps | 19.0\% | 19.0\% | Obps |
| PAT | (₹ mn) | 1,592 | 1,442 | -9\% | 2,242 | 1,774 | -21\% |
| PAT margin | \% | 3.4\% | 3.3\% | -16bps | 3.9\% | 3.3\% | -60bps |
| EPS | ₹ | 3.1 | 2.8 | -8\% | 4.4 | 3.5 | -21\% |

Source: CRISIL Research estimates
Reasons for changes in estimates


## Valuation

Grade: 5/5

The DCF-based fair value is lowered from ₹31 per share to ₹29 because of downward revision in estimates. Our fair value estimate implies an EV/EBITDA multiple of $4.4 \times$ FY17E EBITDA. The stock is currently trading at EV/ EBITDA of $4.3 x$ FY17E EBITDA. At the current market price of ₹ 23 per share, the valuation grade is $5 / 5$.


Source: NSE, CRISIL Research

P/E - premium / discount to CNX 500


Source: NSE, CRISIL Research


Source: NSE, CRISIL Research

P/E movement


[^2]CRISIL IER reports released on Trident Ltd

| Date | Nature of report | Fundamental <br> grade | Fair value | Valuation <br> grade | CMP <br> (on the date of report) |
| :--- | :--- | :---: | :---: | :---: | :---: |
| 24-Feb-14 | Initiating coverage | $3 / 5$ | $₹ 26$ | $5 / 5$ | ₹14 |
| 02-June-14 | Q4FY14 result update | $3 / 5$ | $₹ 26$ | $5 / 5$ | ₹17 |
| 21-Aug-14 | Q1FY15 result update | $3 / 5$ | $₹ 31$ | $5 / 5$ | ₹24 |
| 20-Nov-14 | Q2FY15 result update | $3 / 5$ | $₹ 31$ | $3 / 5$ | ₹29 |
| 10-Mar-15 | Q3FY15 result update | $3 / 5$ | $₹ 31$ | $5 / 5$ | ₹23 |
| 12-June-15 | Q4FY15 result update | $3 / 5$ | $₹ 29$ | $5 / 5$ | ₹23 |

## Annexure: Financials (Consolidated)

Income statement

| (₹ mn) | FY13 | FY14 | FY15\# | FY16E | FY17E |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Operating income | 33,947 | 38,775 | 37,860 | 44,359 | 53,416 |
| EBITDA | 5,673 | 7,405 | 6,915 | 8,221 | 10,167 |
| EBITDA margin | 16.7\% | 19.1\% | 18.3\% | 18.5\% | 19.0\% |
| Depreciation | 2,614 | 2,684 | 3,213 | 3,888 | 4,726 |
| EBIT | 3,059 | 4,721 | 3,702 | 4,334 | 5,441 |
| Interest | 2,353 | 2,103 | 2,060 | 2,370 | 3,084 |
| Operating PBT | 706 | 2,617 | 1,642 | 1,963 | 2,357 |
| Other income | 59 | 4 | 37 | 40 | 40 |
| Exceptional inc/(exp) | 38 | (16) | - | - | - |
| PBT | 803 | 2,605 | 1,679 | 2,003 | 2,397 |
| Tax provision | 310 | 665 | 501 | 561 | 623 |
| Minority interest | - | - | - | - | - |
| PAT (Reported) | 493 | 1,940 | 1,178 | 1,442 | 1,774 |
| Less: Exceptionals | 38 | (16) | - | - | - |
| Adjusted PAT | 455 | 1,956 | 1,178 | 1,442 | 1,774 |
| Ratios |  |  |  |  |  |
|  | FY13 | FY14 | FY15\# | FY16E | FY17E |
| Growth |  |  |  |  |  |
| Operating income (\%) | 21.3 | 14.2 | (2.4) | 17.2 | 20.4 |
| EBITDA (\%) | 80.7 | 30.5 | (6.6) | 18.9 | 23.7 |
| Adj PAT (\%) | (213.9) | 329.8 | (39.8) | 22.4 | 23.0 |
| Adj EPS (\%) | (212.1) | 329.4 | (60.8) | 15.2 | 23.0 |
| Profitability |  |  |  |  |  |
| EBITDA margin (\%) | 16.7 | 19.1 | 18.3 | 18.5 | 19.0 |
| Adj PAT Margin (\%) | 1.3 | 5.0 | 3.1 | 3.3 | 3.3 |
| RoE (\%) | 6.7 | 23.9 | 9.9 | 9.6 | 10.9 |
| RoCE (\%) | 10.4 | 16.4 | 10.8 | 9.4 | 10.8 |
| RolC (\%) | 10.0 | 14.8 | 9.9 | 8.5 | 9.8 |
| Valuations |  |  |  |  |  |
| Price-earnings (x) | 16.4 | 3.8 | 9.7 | 8.5 | 6.9 |
| Price-book (x) | 1.1 | 0.8 | 0.8 | 0.8 | 0.7 |
| EV/EBITDA ( x ) | 5.2 | 3.5 | 5.4 | 5.8 | 4.3 |
| EV/Sales (x) | 0.9 | 0.7 | 1.0 | 1.1 | 0.8 |
| Dividend payout ratio (\%) | - | 6.9 | 20.3 | 20.8 | 20.8 |
| Dividend yield (\%) | - | 1.8 | 2.1 | 2.5 | 3.0 |
| B/S ratios |  |  |  |  |  |
| Inventory days | 77 | 63 | 73 | 71 | 71 |
| Creditors days | 29 | 30 | 36 | 33 | 33 |
| Debtor days | 28 | 27 | 21 | 26 | 26 |
| Working capital days | 103 | 82 | 93 | 94 | 91 |
| Gross asset turnover (x) | 1.0 | 1.1 | 0.9 | 0.8 | 0.8 |
| Net asset turnover (x) | 1.7 | 2.1 | 1.6 | 1.3 | 1.4 |
| Sales/operating assets ( x ) | 1.2 | 1.4 | 1.1 | 1.0 | 1.4 |
| Current ratio (x) | 4.0 | 3.0 | 2.8 | 2.9 | 2.9 |
| Debt-equity (x) | 3.2 | 2.0 | 1.8 | 2.3 | 1.9 |
| Net debt/equity (x) | 3.1 | 2.0 | 1.8 | 2.3 | 1.9 |
| Interest coverage | 1.3 | 2.2 | 1.8 | 1.8 | 1.8 |
| Per share |  |  |  |  |  |
|  | FY13 | FY14 | FY15\# | FY16E | FY17E |
| Adj EPS (₹) | 1.5 | 6.3 | 2.5 | 2.8 | 3.5 |
| CEPS | 9.9 | 14.9 | 9.2 | 10.5 | 12.8 |
| Book value | 22.7 | 29.8 | 30.4 | 30.8 | 33.4 |
| Dividend (₹) | - | 0.4 | 0.5 | 0.6 | 0.7 |
| Actual o/s shares (mn) | 310.8 | 311.1 | 478.1 | 508.0 | 508.0 |

Balance Sheet

| (₹ mn) | FY12 | FY13 | FY14 | FY15\# | FY16E | FY17E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Liabilities |  |  |  |  |  |  |
| Equity share capital | 3,058 | 3,108 | 3,111 | 5,086 | 5,086 | 5,086 |
| Reserves | 3,447 | 3,953 | 6,167 | 9,467 | 10,549 | 11,879 |
| Minorities | - | - | - | - | - | - |
| Net worth | 6,506 | 7,061 | 9,278 | 14,553 | 15,635 | 16,965 |
| Convertible debt | - | - | - | - | - | - |
| Other debt | 22,837 | 22,398 | 18,957 | 25,800 | 35,917 | 32,080 |
| Total debt | 22,837 | 22,398 | 18,957 | 25,800 | 35,917 | 32,080 |
| Deferred tax liability (net) | 760 | 1,070 | 1,082 | 1,241 | 1,242 | 1,242 |
| Total liabilities | 30,102 | 30,530 | 29,318 | 41,596 | 52,795 | 50,288 |
| Assets |  |  |  |  |  |  |
| Net fixed assets | 21,400 | 19,622 | 17,912 | 28,228 | 40,859 | 36,433 |
| Capital WIP | 381 | 449 | 1,047 | 3,100 | - | - |
| Total fixed assets | 21,781 | 20,071 | 18,960 | 31,328 | 40,859 | 36,433 |
| Investments | 613 | 764 | 1,566 | 254 | 254 | 254 |
| Current assets |  |  |  |  |  |  |
| Inventory | 5,204 | 6,911 | 6,429 | 7,508 | 8,507 | 10,244 |
| Sundry debtors | 2,009 | 2,517 | 2,804 | 2,196 | 3,172 | 3,791 |
| Loans and advances | 3,515 | 3,174 | 3,501 | 5,364 | 5,619 | 6,232 |
| Cash \& bank balance | 162 | 185 | 116 | 170 | 150 | 154 |
| Marketable securities | 12 | 25 | 55 | 55 | 55 | 55 |
| Total current assets | 10,902 | 12,812 | 12,904 | 15,292 | 17,504 | 20,475 |
| Total current liabilities | 3,273 | 3,177 | 4,242 | 5,408 | 5,952 | 7,004 |
| Net current assets | 7,629 | 9,635 | 8,662 | 9,884 | 11,553 | 13,471 |
| Intangibles/Misc. expenditure | 79 | 60 | 130 | 130 | 130 | 130 |
| Total assets | 30,102 | 30,530 | 29,317 | 41,595 | 52,794 | 50,287 |
| Cash flow |  |  |  |  |  |  |
| (₹ mn) | FY12 | FY13 | FY14 | FY15\# | FY16E | FY17E |
| Pre-tax profit | (591) | 765 | 2,622 | 1,679 | 2,003 | 2,397 |
| Total tax paid | 38 | - | (653) | (341) | (561) | (623) |
| Depreciation | 2,075 | 2,614 | 2,684 | 3,213 | 3,888 | 4,726 |
| Working capital changes | 344 | $(1,970)$ | 933 | $(1,168)$ | $(1,688)$ | $(1,915)$ |
| Net cash from operations | 1,866 | 1,410 | 5,586 | 3,384 | 3,642 | 4,584 |
| Cash from investments |  |  |  |  |  |  |
| Capital expenditure | $(7,014)$ | (885) | $(1,642)$ | $(15,582)$ | $(13,418)$ | (300) |
| Investments and others | (150) | (164) | (832) | 1,313 | - |  |
| Net cash from investments | $(7,164)$ | $(1,050)$ | $(2,474)$ | $(14,269)$ | $(13,418)$ | (300) |
| Cash from financing |  |  |  |  |  |  |
| Equity raised/(repaid) | 1,047 | 85 | 3 | 4,516 | - | - |
| Debt raised/(repaid) | 3,803 | (438) | $(3,441)$ | 6,843 | 10,117 | $(3,838)$ |
| Dividend (incl. tax) | - | - | (157) | (288) | (361) | (443) |
| Others (incl extraordinaries) | 543 | 15 | 415 | (132) | 0 | (0) |
| Net cash from financing | 5,392 | (338) | $(3,180)$ | 10,939 | 9,756 | $(4,281)$ |
| Change in cash position | 95 | 23 | (69) | 54 | (20) | 3 |
| Closing cash | 162 | 185 | 116 | 170 | 150 | 154 |
| Quarterly financials |  |  |  |  |  |  |
| ( $\mathrm{m}^{\text {m }}$ ) | Q3FY14 | Q4FY14 | Q1FY15 | Q2FY15 | Q3FY15 | Q4FY15 |
| Net Sales | 10,209 | 9,313 | 9,133 | 9,617 | 9,313 | 9,780 |
| Change ( $q-0-q$ ) |  | -9\% | -2\% | 5\% | -3\% | 5\% |
| EBITDA | 1,836 | 1,595 | 1,825 | 1,544 | 1,595 | 1,953 |
| Change ( $q-0-q$ ) |  | -13\% | 14\% | -15\% | 3\% | 22\% |
| EBITDA margin | 18\% | 17\% | 20\% | 16\% | 17\% | 20\% |
| PAT | 509 | 241 | 323 | 210 | 241 | 407 |
| Adj PAT | 509 | 241 | 323 | 210 | 241 | 407 |
| Change ( $q-0-q$ ) |  | -53\% | 34\% | -35\% | 15\% | 69\% |
| Adj PAT margin | 5\% | 3\% | 4\% | 2\% | 3\% | 4\% |
| Adj EPS | 1.6 | 0.5 | 0.7 | 0.5 | 0.5 | 0.8 |

[^3]Source: CRISIL Research

This page is intentionally left blank

## CRISIL IER Independent Equity Research

## CRISIL Research Team

| Senior Director |  |  |  |
| :--- | :--- | :--- | :--- |
| Manish Jaiswal | CRISIL Research | +912233428290 | manish.jaiswal@crisil.com |
|  |  |  |  |
| Analytical Contacts | +912233423137 | prasad.koparkar@crisil.com |  |
| Prasad Koparkar | Senior Director, Industry \& Customised Research | +912233424091 | binaifer.jehani@crisil.com |
| Binaifer Jehani | Director, Customised Research | +912233423342 | $\underline{\text { manoj.damle@crisil.com }}$ |
| Manoj Damle | Director, Customised Research | +912233423554 | $\underline{\text { manoj.mohta@crisil.com }}$ |
| Manoj Mohta | Director, Customised Research | +912233428091 | iiiu.vidyadharan@crisil.com |
| Jiju Vidyadharan | Director, Funds \& Fixed Income Research | +912233423530 | ajay.srinivasan@crisil.com |
| Ajay Srinivasan | Director, Industry Research | +912233423574 | $\underline{\text { rahul.prithiani@crisil.com }}$ |
| Rahul Prithiani | Director, Industry Research | +912233423567 | ajay.dsouza@crisil.com |
| Ajay D'Souza | Director, New Product Development |  |  |

Business Development

| Prosenjit Ghosh | Director, Industry \& Customised Research | +919920656299 | prosenjit.ghosh@crisil.com |  |
| :--- | :--- | :--- | :--- | :--- |
| Megha Agrawal | Associate Director |  | +919867390805 | $\underline{\text { megha.agrawal@crisil.com }}$ |
| Neeta Muliyil | Associate Director |  | +919920199973 | $\underline{\text { neeta.muliyil@crisil.com }}$ |
| Ankesh Baghel | Regional Manager | (West) | +919819121510 | $\underline{\text { ankesh.baghel@crisil.com }}$ |
| Ravi Lath | Regional Manager | (West) | +919820062424 | $\underline{\text { ravi.lath@crisil.com }}$ |
| Siddhartha Biswas | Regional Manager | (West) | +919920036346 | $\underline{\text { siddhartha.biswas@crisil.com }}$ |
| Manish Gupta | Regional Manager | (North) | +919971023111 | $\underline{\text { manish.gupta1@crisil.com }}$ |
| Saurabh Sabharwal | Regional Manager | (North) | +919650228684 | $\underline{\text { saurabh.sabharwal@crisil.com }}$ |
| Priyanka Murarka | Regional Manager | (East) | +919903060685 | priyanka.murarka@crisil.com |
| Naveena R | Regional Manager | (Karnataka \& Kerala) | +919538333088 | $\underline{\text { naveena.r@crisil.com }}$ |
| Sanjay Krishnaa | Regional Manager | (Tamil Nadu \& AP) | +919884806606 | $\underline{\text { sanjay.krishnaa@crisil.com }}$ |

## Our Capabilities

## Making Markets Function Better

## Economy and Industry Research

- Largest team of economy and industry research analysts in India
- Acknowledged premium, high quality research provider with track record spanning two decades
- $95 \%$ of India's commercial banking industry by asset base uses our industry research for credit decisions
- Coverage on 86 industries: We provide analysis and forecast on key industry parameters including demand, supply, prices, investments and profitability, along with insightful opinions on emerging trends and impact of key events
- Research on sectors and clusters dominated by small and medium enterprises covering analysis of relative attractiveness, growth prospects and financial performance
- High-end customised research for many leading Indian and global corporates in areas such as market sizing, demand forecasting, project feasibility and entry strategy


## Funds and Fixed Income Research

- Largest and most comprehensive database on India's debt market, covering more than 18,000 securities
- Largest provider of fixed income valuations in India
- Provide valuation for more than ₹81 trillion (US\$ 1,275 billion) of Indian debt securities
- Sole provider of fixed income and hybrid indices to mutual funds and insurance companies; we maintain 37 standard indices and over 100 customised indices
- Ranking of Indian mutual fund schemes covering $75 \%$ of assets under management and ₹9 trillion (US\$ 144 billion) by value
- Business review consultants to The Employees' Provident Fund Organisation (EPFO) and The National Pension System (NPS) Trust in monitoring performance of their fund managers


## Equity and Company Research

- Assigned the first IPO grade in India; graded more than 100 IPOs till date
- Due Diligence and Valuation services across sectors; executed close to 100 valuation assignments
- Due Diligence, IPO Grading and Independent Equity Research for SME companies planning to list or already listed in NSE Emerge platform
- First research house to release exchange-commissioned equity research reports in India; covered 1,488 firms listed and traded on the National Stock Exchange


## Executive Training

- Conducted 1200+ training programs on a wide spectrum of topics including credit, risk, retail finance, treasury, and corporate advisory; trained more than 24,000 professionals till date
- Training programs being conducted in India, Sri Lanka and Bangladesh through an extensive network of well-qualified financial professionals


## Our Office

## Ahmedabad

706, Venus Atlantis
Nr. Reliance Petrol Pump
Prahladnagar, Ahmedabad, India
Phone: +91 7940244500
Fax: +91 7927559863

## Bengaluru

W-101, Sunrise Chambers,
22, Ulsoor Road,
Bengaluru - 560 042, India
Phone: +91 8025580899
+91 8025594802
Fax: +91 8025594801

## Chennai

Thapar House,
43/44, Montieth Road, Egmore,
Chennai - 600 008, India
Phone: +91 442854 6205/06
+914428546093
Fax: +91 4428547531

## Gurgaon

Plot No. 46
Sector 44
Opp. PF Office
Gurgaon - 122 003, India
Phone: +91 1246722000

## Hyderabad

3rd Floor, Uma Chambers
Plot No. 9\&10, Nagarjuna Hills,
(Near Punjagutta Cross Road)
Hyderabad - 500 482, India
Phone: +91 402335 8103/05
Fax: +91 4023357507

## Kolkata

Horizon, Block 'B', 4th Floor
57 Chowringhee Road
Kolkata - 700 071, India
Phone: +91 332289 1949/50
Fax: +91 3322830597

## Pune

1187/17, Ghole Road,
Shivaji Nagar,
Pune - 411 005, India
Phone: +91 202553 9064/67
Fax: +91 2040181930


[^0]:    Source: Company, CRISIL Research

[^1]:    Source: Company, CRISIL Research

[^2]:    Source: NSE, CRISIL Research

[^3]:    \# Based on abridged financials

